Anti-cancer cell therapies and the end of the CRISPR-Cas9 controversy.
Genomics has the potential to significantly improve the efficacy of drugs and develop targeted therapies.
UC Berkeley & UC San Francisco launch gene-editing initiative.
Merck join the SGC with multi-million dollar contribution. Merck have announced a contribution of C$7.5 million to the Structural Genomics Consortium (SGC), joining as a member organisation. The supported project focus on per-competitive research to develop small inhibitory molecules called chemical probes to study epigenetic mechanisms of regulation. In collaboration with leading clinical institutions in […]
NIH breakthrough in gene therapy for methylmalonic acidemia.
Whole-exome sequencing reveals the mutational spectrum of testicular germ cell tumours.